...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Vote - please
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Toniv,  comparatively, Resverlogix accumulated only $375,480 by way of exempt distribution funding in 2023 thus far. The last one was on May 15, 2023, for $176,400.00 (CAN)

It borrowed $1.4 Mil (US) from ZCC as noted in the financials, in 2023.

 

Koo

1 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply